To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.

Completed · Phase 2 · Has a placebo group

Conditions studied: Primary Bile Acid Diarrhea

In brief

The purpose of this study is to determine whether LJN452 improves the symptoms of bile acid diarrhea and to assess its safety and tolerability profile in patients with primary bile acid diarrhea (pBAD) to guide decision-making regarding further clinical development in this indication.

Key facts

Study ID

NCT02713243

Run by

Novartis Pharmaceuticals

People needed

20

Starts

2016-01-16

Expected to finish

2018-01-25

Last updated by the study team

2021-01-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Novartis Investigative Site — Rochester, Minnesota, United States
• Novartis Investigative Site — Harrow, Middlesex, United Kingdom
• Novartis Investigative Site — London, United Kingdom
• Novartis Investigative Site — Sheffield, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.